Diaceutics (LON:DXRX) Insider Purchases £150 in Stock

Diaceutics PLC (LON:DXRX) insider Jordan Clark bought 100 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was bought at an average cost of GBX 150 per share, with a total value of £150.

Jordan Clark also recently made the following trade(s):

• On Tuesday, December 23rd, Jordan Clark bought 117 shares of Diaceutics stock. The stock was purchased at an average price of GBX 128 per share, for a total transaction of £149.76.

Diaceutics Trading Up 1.1%

DXRX opened at GBX 144 on Thursday. Diaceutics PLC has a one year low of GBX 106 and a one year high of GBX 176.25. The business’s 50 day moving average price is GBX 153.09 and its 200 day moving average price is GBX 151.84. The stock has a market capitalization of £121.86 million, a PE ratio of -80.00 and a beta of 0.58. The company has a debt-to-equity ratio of 3.05, a quick ratio of 9.92 and a current ratio of 3.96.

Wall Street Analyst Weigh In

Separately, Shore Capital Group increased their target price on Diaceutics from GBX 180 to GBX 215 and gave the stock a “buy” rating in a research note on Thursday, January 15th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of GBX 193.33.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.